Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cellsCOPPO, Paul; DUSANTER-FOURT, Isabelle; SAINTENY, Francoise et al.Oncogene (Basingstoke). 2003, Vol 22, Num 26, pp 4102-4110, issn 0950-9232, 9 p.Article

Lipocalin 2 is required for BCR-ABL-induced tumorigenesisLENG, X; LIN, H; ADEREM, A et al.Oncogene (Basingstoke). 2008, Vol 27, Num 47, pp 6110-6119, issn 0950-9232, 10 p.Article

BCR―ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patientsDE CARVALHO, D. D; BINATO, R; CASTRO, F. A et al.Oncogene (Basingstoke). 2011, Vol 30, Num 2, pp 223-233, issn 0950-9232, 11 p.Article

JunB is a gatekeeper for B-lymphoid leukemiaOTT, R. G; SIMMA, O; SEXL, V et al.Oncogene (Basingstoke). 2007, Vol 26, Num 33, pp 4863-4871, issn 0950-9232, 9 p.Article

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cellsESSAFI, Abdelkader; FERNANDEZ DE MATTOS, Silvia; HASSEN, Yasmin A. M et al.Oncogene (Basingstoke). 2005, Vol 24, Num 14, pp 2317-2329, issn 0950-9232, 13 p.Article

Gallic acid downregulates matrix metalloproteinase-2 (MMP-2) and MMP-9 in human leukemia cells with expressed Bcr/AblCHEN, Ying-Jung; CHANG, Long-Sen.Molecular nutrition & food research (Print). 2012, Vol 56, Num 9, pp 1398-1412, issn 1613-4125, 15 p.Article

The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblastsDALEY, G. Q; MCLAUGHLIN, J; WITTE, O. N et al.Science (Washington, D.C.). 1987, Vol 237, Num 4814, pp 532-535, issn 0036-8075Article

Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemiaARLINGHAUS, Ralph B.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8560-8567, issn 0950-9232, 8 p.Article

Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell linesDESPLAT, Vanessa; BELLOC, Francis; LAGARDE, Valkrie et al.Cancer. 2005, Vol 103, Num 1, pp 102-110, issn 0008-543X, 9 p.Article

Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatmentDOUET-GUILBERT, Nathalie; MOREL, Frédéric; LE CHARPENTIER, Tiffen et al.Anticancer research. 2004, Vol 24, Num 4, pp 2535-2539, issn 0250-7005, 5 p.Article

AMNI07 (nilotinib) : a novel and selective inhibitor of BCR-ABLWEISBERG, E; MANLEY, P; MESTAN, I et al.British journal of cancer. 2006, Vol 94, Num 12, pp 1765-1769, issn 0007-0920, 5 p.Article

Rin1 is a negative regulator of the IL3 receptor signal transduction pathwaysHUNKER, C. M; GALVIS, A; VEISAGA, M. L et al.Anticancer research. 2006, Vol 26, Num 2A, pp 905-916, issn 0250-7005, 12 p.Article

WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cellsELMAAGACLI, Ahmet H; KOLDEHOFF, Michael; PECENY, Rudolf et al.Haematologica (Roma). 2005, Vol 90, Num 3, pp 326-334, issn 0390-6078, 9 p.Article

The second generation of BCR-ABL tyrosine kinase inhibitors : PIH: New era of leukemia therapyTAUCHI, Tetsuzo; OHYASHIKI, Kazuma.International journal of hematology. 2006, Vol 83, Num 4, pp 294-300, issn 0925-5710, 7 p.Article

Protein chimerism: Novel source of protein diversity in humans adds complexity to bottom-up proteomicsCASADO-VELA, Juan; CARLOS LACAL, Juan; ELORTZA, Felix et al.Proteomics (Weinheim. Print). 2013, Vol 13, Num 1, pp 5-11, issn 1615-9853, 7 p.Article

BCR/ABL modulates protein phosphorylation associated with the etoposide-induced DNA damage responseGRIAUD, François; WILLIAMSON, Andrew J. K; TAYLOR, Samuel et al.Journal of proteomics (Print). 2012, Vol 77, pp 14-26, issn 1874-3919, 13 p.Article

MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-κB activationNAWATA, Ryouhei; YUJIRI, Toshiaki; NAKAMURA, Yukinori et al.Oncogene (Basingstoke). 2003, Vol 22, Num 49, pp 7774-7780, issn 0950-9232, 7 p.Article

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapiesJIANG, X; ZHAO, Y; SMITH, C et al.Leukemia. 2007, Vol 21, Num 5, pp 926-935, issn 0887-6924, 10 p.Article

Inhibition of phosphorylation of p160 BCR within p210 BCR-ABL complexes during early stages of phorbol ester-induced differentiation of K562 cellsCAMPBELL, P. L; DAI LU; JIE QIANG GUO et al.Cell growth and differentiation. 1993, Vol 4, Num 7, pp 581-588, issn 1044-9523Article

Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effectsPERAZZONA, B; LIN, H; SUN, T et al.Oncogene (Basingstoke). 2008, Vol 27, Num 15, pp 2208-2214, issn 0950-9232, 7 p.Article

The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemiaLIHUI WANG; KNIGHT, Katy; LUCAS, Claire et al.Haematologica (Roma). 2006, Vol 91, Num 2, pp 235-239, issn 0390-6078, 5 p.Article

Bcr-Abl induces autocrine IGF-1 signalingLAKSHMIKUTTYAMMA, A; PASTURAL, E; TAKAHASHI, N et al.Oncogene (Basingstoke). 2008, Vol 27, Num 27, pp 3831-3844, issn 0950-9232, 14 p.Article

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translationNOTARI, Mario; NEVIANI, Paolo; PERROTTI, Danilo et al.Blood. 2006, Vol 107, Num 6, pp 2507-2516, issn 0006-4971, 10 p.Article

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen : high efficacy of drug combinationsBRADEEN, Heather A; EIDE, Christopher A; O'HARE, Thomas et al.Blood. 2006, Vol 108, Num 7, pp 2332-2338, issn 0006-4971, 7 p.Article

Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human t-cell responsesPINILLA-LBARZ, Javier; KORONTSVIT, Tatyana; ZAKHALEVA, Victoriya et al.Haematologica (Roma). 2005, Vol 90, Num 10, pp 1324-1332, issn 0390-6078, 9 p.Article